Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Odyssey Health, Inc. Secures Multi-Million-Dollar, Nine-Year Service Contract and Financing Facility for Up to $25 Million
Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.